<DOC>
	<DOCNO>NCT00532779</DOCNO>
	<brief_summary>The purpose study determine whether 2 dos combination naltrexone SR bupropion SR safe effective treatment obesity .</brief_summary>
	<brief_title>A Study Safety Efficacy Two Doses Naltrexone SR/Bupropion SR Placebo Overweight Obese Subjects</brief_title>
	<detailed_description>Two Phase II clinical trial demonstrate combination bupropion SR naltrexone associate great weight loss bupropion SR alone , naltrexone alone , placebo subject uncomplicated obesity . The current study investigate safety efficacy 2 dos combination naltrexone SR bupropion SR compare placebo obese subject uncomplicated obesity overweight/obesity hypertension and/or dyslipidemia .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Female male subject , 18 65 year age ; Have BMI ≥30 ≤45kg/m² subject uncomplicated obesity , BMI ≥27 ≤45kg/m² subject obesity control hypertension and/or dyslipidemia ; Normotensive ( systolic ≤140 mm Hg ; diastolic ≤90 mm Hg ) . Antihypertensive medication allow exception alphaadrenergic blocker clonidine ; medical regimen must stable least 6 week prior randomization ; Medications treatment dyslipidemia allow long medical regimen stable least 6 week prior randomization ; Free opioid medication 7 day prior randomization ; No clinically significant abnormality serum albumin , blood urea nitrogen , creatinine , bilirubin , sodium , potassium , chloride , calcium phosphorus ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within 2.5 x upper limit normal range ( ULN ) ; No clinically significant abnormality hematocrit , white blood cell ( WBC ) count , white cell differential , platelet ; Fasting glucose &lt; 126 mg/dL hypoglycemic agent , fast triglyceride &lt; 400 mg/dL ; No clinically significant abnormality urinalysis ; TSH within normal limit normal T3 , TSH normal limit ; Negative serum pregnancy test woman childbearing potential ; Negative urine drug screen ; IDSSR score &lt; 2 item 5 ( sadness ) , 6 ( irritability ) , 7 ( anxiety/tension ) 18 ( suicidality ) , IDSSR total score &lt; 30 ; Women child bear potential nonlactating agree use effective contraception throughout study period 30 day discontinuation study drug ; Able comply require study procedure schedule ; Able speak read English ; Willing able give write informed consent . Obesity known endocrine origin ( e.g. , untreated hypothyroidism , Cushing 's syndrome , establish Polycystic Ovary Syndrome ) ; Serious medical condition ( include limit ongoing renal hepatic insufficiency , Class III IV congestive heart failure ; myocardial infarction , history angina pectoris , claudication , acute limb ischemia within previous 6 month ; lifetime history stroke ) ; History malignancy within previous 5 year exception nonmelanoma skin cancer surgically cure cervical cancer ; A lifetime history serious psychiatric illness , include lifetime history bipolar disorder , schizophrenia psychosis , bulimia , anorexia nervosa ; Current serious psychiatric illness include severe personality disorder , ( e.g . borderline antisocial ) , current severe major depressive disorder , recent ( previous 6 month ) suicide attempt , current active suicidal ideation , recent hospitalization due psychiatric illness ; A response bipolar disorder question indicate presence bipolar disorder ; In need medication treatment psychiatric disorder ( exception shortterm insomnia ) within previous 6 month prior randomization ; History drug alcohol abuse dependence ( exception nicotine dependence ) within 1 year prior study initiation ; Type 1 Type 2 diabetes mellitus ; Screening ECG correct QT interval method Bazett ( QTcB ) &gt; 450 msec ( men ) &gt; 470 millisecond ( msec ) ( woman ) presence clinically significant cardiac abnormality , include limited pattern consistent myocardial ischemia , electrolyte abnormality , atrial ventricular dysrhythmia significant conduction abnormality ; Excluded concomitant medication : psychotropic agent ( include antipsychotic , antidepressant , anxiolytic , mood stabilizer , anticonvulsant agent agent treatment Attention Deficit Disorder ) exception low dose benzodiazepine hypnotic agent treatment insomnia ( 2 mg lorazepam/day equivalent dose benzodiazepine hypnotic agent ) ; anorectic weight loss agent ; overthecounter dietary supplement herbs psychoactive , appetite weight effect ; alphaadrenergic blocker ; dopamine agonist ; clonidine ; coumadin ; theophylline ; cimetidine ; oral corticosteroid ; cholestyramine , cholestypol , Depo Provera® ; smoke cessation agent ; use opioid opioidlike medication , include analgesic antitussive ; History surgical device ( e.g. , gastric banding ) intervention obesity ; History seizures etiology , predisposition seizure ( e.g. , history cerebrovascular accident , head trauma ≥5 minute loss consciousness , concussion symptom last ≥15 minute , brain surgery , skull fracture , subdural hematoma , febrile seizure ) ; History treatment bupropion naltrexone within precede 12 month ; History hypersensitivity intolerance bupropion naltrexone ; Initiation discontinuation tobacco product include inhaled tobacco ( cigarette , cigar , pipe , etc ) , chew tobacco snuff 3 month prior randomization plan study participation . Use nicotine replacement product ( nicotine gum , patch ) study participation allow ; Use drug , herb , dietary supplement believe significantly affect body weight participation weight loss management program within one month prior randomization ; Loss gain 4.0 kilogram within 3 month prior randomization ; Pregnant breastfeed woman plan become pregnant study period within 30 day discontinue study drug ; Planned surgical procedure impact conduct study ; Use investigational drug , device procedure within previous 30 day ; Participation previous clinical trial sponsor Orexigen Therapeutics ; Any condition opinion investigator make subject unsuitable inclusion study ; Investigators , study personnel , sponsor representative immediate family .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Antiobesity agent</keyword>
	<keyword>Antiobesity drug</keyword>
	<keyword>Overweight drug therapy</keyword>
	<keyword>Obese drug therapy</keyword>
	<keyword>Weight loss drug effect</keyword>
	<keyword>Bupropion administration dosage</keyword>
	<keyword>Naltrexone administration dosage</keyword>
	<keyword>Double blind method</keyword>
	<keyword>Combination drug therapy</keyword>
	<keyword>Delayed action preparation</keyword>
</DOC>